Literature DB >> 7776836

Metabolism of delta 9-tetrahydrocannabinol by cytochrome P450 isozymes purified from hepatic microsomes of monkeys.

T Matsunaga1, Y Iwawaki, K Watanabe, I Yamamoto, T Kageyama, H Yoshimura.   

Abstract

The most abundant metabolite of delta 9-tetrahydrocannabinol (delta 9-THC) formed with hepatic microsomes of monkeys was 11-OH-delta 9-THC, followed by 8 alpha-OH-, 8 beta-OH- and 3'-OH-delta 9-THCs. Two cytochrome P450 isozymes, P450RM-A and P450JM-C, were purified from monkey hepatic microsomes and found to have a molecular weight of 51,000. In the reconstituted system, the activities of P450RM-A towards formation of 11-OH-, 8 alpha-OH-, 8 beta-OH- and 3'-OH-delta 9-THCs were 19-, 40-, 22- and 10-fold higher, respectively, than the corresponding activities of the hepatic microsomes. The activity of P450JM-C towards formation of 3'-OH-delta 9-THC was 10-fold higher than that of P450RM-A, while the activities of both isozymes for 11- and 8 alpha-hydroxylation were not so much different and the 8 beta-hydroxylation activity was 14-fold higher in P450RM-A than in P450JM-C. Antibodies against P450RM-A and P450JM-C markedly inhibited the microsomal formation of 11-OH- and 8 alpha-OH-delta 9-THCs, and 3'-OH-delta 9-THC, respectively. These results suggest that P450RM-A and P450JM-C are major isozymes responsible for the formation of 11-OH- and 8 alpha-OH-delta 9-THCs, and 3'-OH-delta 9-THC, respectively, in monkeys.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7776836     DOI: 10.1016/0024-3205(95)00193-a

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  12 in total

1.  Comparative effects of pulmonary and parenteral Δ⁹-tetrahydrocannabinol exposure on extinction of opiate-induced conditioned aversion in rats.

Authors:  Laurie A Manwell; Paul E Mallet
Journal:  Psychopharmacology (Berl)       Date:  2014-11-15       Impact factor: 4.530

2.  Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration.

Authors:  David M Schwope; Erin L Karschner; David A Gorelick; Marilyn A Huestis
Journal:  Clin Chem       Date:  2011-08-11       Impact factor: 8.327

Review 3.  Human cannabinoid pharmacokinetics.

Authors:  Marilyn A Huestis
Journal:  Chem Biodivers       Date:  2007-08       Impact factor: 2.408

4.  Direct quantification of cannabinoids and cannabinoid glucuronides in whole blood by liquid chromatography-tandem mass spectrometry.

Authors:  David M Schwope; Karl B Scheidweiler; Marilyn A Huestis
Journal:  Anal Bioanal Chem       Date:  2011-07-05       Impact factor: 4.142

Review 5.  Pharmacokinetics and pharmacodynamics of cannabinoids.

Authors:  Franjo Grotenhermen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

6.  Cannabinoids in exhaled breath following controlled administration of smoked cannabis.

Authors:  Sarah K Himes; Karl B Scheidweiler; Olof Beck; David A Gorelick; Nathalie A Desrosiers; Marilyn A Huestis
Journal:  Clin Chem       Date:  2013-09-17       Impact factor: 8.327

7.  11-Nor-9-carboxy-∆9-tetrahydrocannabinol quantification in human oral fluid by liquid chromatography-tandem mass spectrometry.

Authors:  Karl B Scheidweiler; Sarah K Himes; Xiaohong Chen; Hua-Fen Liu; Marilyn A Huestis
Journal:  Anal Bioanal Chem       Date:  2013-05-17       Impact factor: 4.142

8.  Psychomotor performance, subjective and physiological effects and whole blood Δ⁹-tetrahydrocannabinol concentrations in heavy, chronic cannabis smokers following acute smoked cannabis.

Authors:  David M Schwope; Wendy M Bosker; Johannes G Ramaekers; David A Gorelick; Marilyn A Huestis
Journal:  J Anal Toxicol       Date:  2012-05-15       Impact factor: 3.367

Review 9.  Cannabis use, abuse, and withdrawal: Cannabinergic mechanisms, clinical, and preclinical findings.

Authors:  Andrew J Kesner; David M Lovinger
Journal:  J Neurochem       Date:  2021-05-16       Impact factor: 5.546

Review 10.  Cannabis and Its Secondary Metabolites: Their Use as Therapeutic Drugs, Toxicological Aspects, and Analytical Determination.

Authors:  Joana Gonçalves; Tiago Rosado; Sofia Soares; Ana Y Simão; Débora Caramelo; Ângelo Luís; Nicolás Fernández; Mário Barroso; Eugenia Gallardo; Ana Paula Duarte
Journal:  Medicines (Basel)       Date:  2019-02-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.